Inhibikase Therapeutics (IKT) POS AM 31 Mar 23 Prospectus update (post-effective amendment) Financial data

Cover Page

Cover Page	12 Months Ended
	Dec. 31, 2022
Document Information [Line Items]
Document Type	POS AM
Amendment Flag	true
Entity Registrant Name	INHIBIKASE THERAPEUTICS, INC.
Entity Central Index Key	0001750149
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	false
Entity Tax Identification Number	26-3407249
Entity Address, Address Line One	3350 Riverwood Parkway SE
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30339
City Area Code	678
Local Phone Number	392-3419
Entity Incorporation, State or Country Code	DE
Entity Primary SIC Number	2836
Amendment Description	On February 1, 2023, we filed a registration statement on Form S-1 (No. 333-269521) (the “Registration Statement”), which registered for resale from time to time (i) up to 11,627,908 shares of common stock, par value $0.001 per share (the “Common Stock”), which the selling stockholders (the “Selling Stockholders”) may acquire upon the exercise of outstanding warrants (the “Common Warrants”), (ii) up to 4,883,721 shares of Common Stock, which the Selling Stockholders may acquire upon the exercise of outstanding pre-funded warrants (the “Pre-Funded Warrants”), and (iii) up to 406,977 shares of Common Stock, which the Selling Stockholders may acquire upon the exercise of outstanding placement agent warrants (the “Placement Agent Warrants”, and together with the Common Warrants, and Pre-Funded Warrants, the “Warrants”). We issued the Common Warrants and Pre-Funded Warrants to the Selling Stockholders in private placements concurrent with a registered direct offering of 2,800,789 shares of Common Stock and Pre-Funded Warrants to purchase 3,943,398 shares of Common Stock. We issued the Placement Agent Warrants to Selling Stockholders as designees of H.C. Wainwright & Co., as placement agent fees for serving as the exclusive placement agent in the registered direct offering and concurrent private placements. The closing of the issuance and sale of these securities was consummated on January 27, 2023. The Registration Statement was declared effective by the Securities and Exchange Commission on February 7, 2023. This post-effective amendment is being filed to include information from our Annual Report on Form10-K for the year ended December 31, 2022 that was filed on March 31, 2023. No additional securities are being registered under this post-effective amendment and all applicable registration and filing fees were paid at the time of the original filing of the Registration Statement.
Business Contact [Member]
Document Information [Line Items]
Entity Address, Address Line One	3350 Riverwood Parkway SE
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30339
City Area Code	678
Local Phone Number	392-3419
Contact Personnel Name	Milton H. Werner

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 7,188,553	$ 40,750,133
Marketable securities	15,861,620	0
Accounts receivable	39,881	110,141
Prepaid research and development	1,117,616	107,000
Prepaid expenses and other current assets	163,452	1,502,725
Total current assets	24,371,122	42,469,999
Equipment and improvements, net	236,532	0
Right-of-use asset	328,643	0
Total assets	24,936,297	42,469,999
Current liabilities:
Accounts payable	1,151,173	1,089,778
Lease obligation, current	145,836	0
Accrued expenses and other current liabilities	2,398,436	2,715,761
Notes payable	0	248,911
Total current liabilities	3,695,445	4,054,450
Lease obligations, net of current portion	205,451	0
Total liabilities	3,900,896	4,054,450
Commitments and contingencies (see Note 14)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2022 and 2021; 0 shares issued and outstanding at December 31, 2022 and 2021	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 25,227,051 and 25,155,198 shares issued and outstanding at December 31, 2022 and 2021	25,227	25,155
Additional paid-in capital	68,777,298	68,208,081
Accumulated other comprehensive income	104,718	0
Accumulated deficit	(47,871,842)	(29,817,687)
Total stockholders' equity	21,035,401	38,415,549
Total liabilities and stockholders' equity	$ 24,936,297	$ 42,469,999

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	25,227,051	25,155,198
Common stock, shares outstanding	25,227,051	25,155,198

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Grant revenue	$ 123,440	$ 3,100,605
Costs and expenses:
Research and development	12,034,985	11,359,104
Selling, general and administrative	6,217,063	6,507,641
Total costs and expenses	18,252,048	17,866,745
Loss from operations	(18,128,608)	(14,766,140)
Interest income (expense)	74,453	(19,923)
Net loss	(18,054,155)	(14,786,063)
Other comprehensive income, net of taxes:
Unrealized gains on marketable securities	104,718	0
Comprehensive loss	$ (17,949,437)	$ (14,786,063)
Net loss per share - basic	$ (0.72)	$ (0.81)
Net loss per share - diluted	$ (0.72)	$ (0.81)
Weighted average number of common share - basic	25,211,726	18,209,198
Weighted average number of common share - diluted	25,211,726	18,209,198

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Total	IPO	Common Stock	Common Stock IPO	Additional Paid-In Capital	Additional Paid-In Capital IPO	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning balance at Dec. 31, 2020	$ 9,784,356		$ 10,051		$ 24,805,929			$ (15,031,624)
Beginning balance, Shares at Dec. 31, 2020			10,050,849
Stock-based compensation expense	1,531,876				1,531,876
Issuance of warrants	688,784				688,784
Issuance of common stock	60,391	$ 41,135,357	$ 9	$ 15,000	60,382	$ 41,120,357
Issuance of common stock, Shares			9,000	15,000,000
Conversion of notes	848		$ 95		753
Conversion of notes, Shares			95,349
Net loss	(14,786,063)							(14,786,063)
Ending balance at Dec. 31, 2021	$ 38,415,549		$ 25,155		68,208,081			(29,817,687)
Ending balance, Shares at Dec. 31, 2021	25,155,198		25,155,198
Stock-based compensation expense	$ 458,147				458,147
Issuance of warrants	0
Issuance of common stock	67,000		$ 50		66,950
Issuance of common stock, Shares			50,000
Stock Issued During Period, Value, Stock Options Exercised	44,142		$ 22		44,120
Issuance of common stock, stock options exercised, Shares			21,853
Other comprehensive income	104,718						$ 104,718
Net loss	(18,054,155)							(18,054,155)
Ending balance at Dec. 31, 2022	$ 21,035,401		$ 25,227		$ 68,777,298		$ 104,718	$ (47,871,842)
Ending balance, Shares at Dec. 31, 2022	25,227,051		25,227,051

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating activities
Net loss	$ (18,054,155)	$ (14,786,063)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	6,723	0
Stock-based compensation expense	458,147	1,531,876
Non-cash consulting fees	67,000	60,391
Non-cash PPP loan forgiveness	0	(27,550)
Warrant expense	0	688,784
Changes in operating assets and liabilities:
Accounts receivable	70,258	(110,141)
Operating lease right-of-use assets	38,055	0
Prepaid expenses and other assets	1,339,273	(1,447,888)
Prepaid research and development	(1,010,616)	667,356
Accounts payable	61,395	(630,902)
Operating lease liabilities	(9,859)
Accrued expenses and other current liabilities	(317,324)	2,082,827
Deferred revenue	0	(2,325,741)
Net cash used in operating activities	(17,351,103)	(14,297,051)
Investing activities
Purchases of investments — marketable securities	(20,725,462)	0
Maturities of investments — marketable securities	4,963,009	0
Purchases of equipment and improvements	(243,255)	0
Net cash used in investing activities	(16,005,708)	0
Financing activities
Issuance of common stock from exercise of stock options	44,142	78,500
Payment of employee taxes in connection with stock option exercise	0	(77,652)
Proceeds from issuance of common stock from public offerings, net of issuance costs	0	41,135,357
Repayments of note payable	(248,911)	(42,534)
Net cash (used in)/provided by financing activities	(204,769)	41,093,671
Net (decrease)/increase in cash and cash equivalents	(33,561,580)	26,796,620
Cash and cash equivalents at beginning of year	40,750,133	13,953,513
Cash and cash equivalents at end of year	7,188,553	40,750,133
Supplemental disclosures of cash flow information
Cash paid for interest	973	1,148
PPP loans forgiveness	0	27,550
Cash paid for amounts included in the measurement of operating lease liabilities	$ 5,553	$ 0

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	1. Nature of Business We are a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related IkT-148009, c-Abl IkT-148009, IkT-148009 Parkinson’s-related IkT-148009 IkT-148009 The Company is also developing platform technologies for alternate ways to deliver protein kinase inhibitors in patients. Our first example of this technology is IkT-001Pro, (SP-CML). IkT-001Pro two-part 96-hour IkT-001Pro IkT-001Pro standard-of-care SP-CML. IkT-001Pro. IkT-001Pro IkT-001Pro IkT-001Pro standard-of-care SP-CML two-period-wait-list- For both IkT-148009 IkT-001Pro, IkT-001Pro IkT-148009 Liquidity The Company has recognized recurring losses. At December 31, 2022, the Company had working capital of $20,675,677, an accumulated deficit of $47,871,842, cash and cash equivalents of $7,188,553, marketable securities of $15,861,620 and accounts payable and accrued expenses of $3,549,609. The future success of the Company is dependent on its ability to successfully obtain additional working capital, obtain regulatory approval for and successfully launch and commercialize its product candidates and to ultimately attain profitable operations. Historically, the Company has funded its operations primarily through cash received in connection with revenue from its various grant programs. In addition, in December 2020, June 2021 and January 2023 the Company raised approximately $14.6 million, $41.1 million and $8.7 million in net proceeds for working capital from its initial public offering (“IPO”), June 2021 Offering and January 2023 Offering, respectively. The Company is subject to a variety of risks similar to other early-stage life science companies including, but not limited to, the successful development, regulatory approval, and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional working capital. The Company has incurred significant research and development expenses and general and administrative expenses related to its product candidate programs. The Company anticipates costs and expenses to increase in the future as the Company continues to develop its product candidates. The Company may seek to fund its operations through additional public equity, private equity, or debt financings, as well as other sources. However, the Company may be unable to raise additional working capital, or if it is able to raise additional capital, it may be unable to do so on commercially favorable terms. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations and financial condition and the Company’s ability to continue to develop its product candidates. The Company estimates that its working capital at December 31, 2022 and funds raised from the January 2023 Offering is sufficient to fund its normal operations into the fourth quarter of 2024. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements for the years ended December 31, 2022 and 2021, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for financial information, which prescribes elimination of all significant inter-company accounts and transactions in the accounts of the Company and its wholly owned subsidiary, IKT Securities Corporation, which was incorporated in the Commonwealth of Massachusetts in December 2021. In the opinion of management, these consolidated financial statements reflect all adjustments which are necessary for a fair statement of the Company’s financial position and results of its operations, as of and for the periods presented. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). Consolidation The accompanying consolidated financial statements include the Company and its wholly owned subsidiary, IKT Securities Corporation. The Company has eliminated all inter-company transactions for the years presented. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company utilizes certain estimates in the determination of our liquidity and working capital adequacy, the fair value of its stock options and warrants, deferred tax valuation allowances and revenue recognition, to record expenses relating to research and development contracts and accrued expenses. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates. Off-Balance The Company has no significant off-balance The Company has not experienced any losses in such accounts and management believes that the Company does not have significant credit risk with respect to such cash and cash equivalents and marketable securities. For the years ended December 31, 2022 and 2021, the Company derived 100% of its total revenue from a single source, the United States Government, in the form of federal research grants. Cash and cash equivalents The Company considers all highly liquid investments that are readily convertible to known amounts of cash with original maturities of three months or less at date of purchase to be cash equivalents. The Company had cash and cash equivalents of $ Accounts receivable The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding invoices and the overall quality and age of those invoices. To date, the Company has no write-offs no Leases The Company accounts for its leases under ASU 2021-09, 2018-10, Leases right-of-use Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any of these criteria. For all leases at the lease commencement date, a right-of-use right-of-use The right-of-use right-of-use Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease cost for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease cost are any variable lease payments incurred in the period that are not included in the initial lease liability and lease payments incurred in the period for any leases with an initial term of 12 months or less. Lease cost for finance leases consists of the amortization of the right-of-use The Company has made an accounting policy election to not recognize leases with an initial term of 12 months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis in our consolidated statements of operations and comprehensive loss over the lease term. Equipment and Improvements Equipment and improvements are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated usefulness from three to five years for network equipment, office equipment, and furniture classified as fixed assets. Estimated Useful Economic Life Leasehold property improvements, right of use assets Lesser of lease term or useful life Furniture and office equipment 5 years Lab equipment 3 Years IT equipment 3 years Fair Value Measurements The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements. • Level 1 — Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access; • Level 2 — Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates; and • Level 3 — Inputs are unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services. The pricing services utilize industry standard valuation models, including both Marketable Securities The Company’s marketable securities consist of U.S. Treasury securities with maturities of less than one year which are classified as available-for-sale Available-for-sale Available-for-sale Revenue Recognition The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange Revenue from Contracts with Customers Research and Development Costs Costs incurred in the research and development of the Company’s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with performing services under grant revenue contracts and include salaries and benefits, stock compensation, research-related subcontractors and consultants, supplies and overhead costs. Advance payments made to suppliers and contract research organizations are classified as prepaid research and development and are expensed as research and development as the supplies are consumed and the contract services are provided. Stock-Based Compensation The Company has a stock-based compensation plan which is more fully described in Note 9. The Company records stock-based compensation for options granted to employees and to members of the board of directors for their services on the board of directors, based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the applicable service period, which is generally one to two years. The Company accounts for non-employee non-employee The Company uses the Black-Scholes-Merton option-pricing model to determine the fair value of stock options. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that the historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of Company specific historical and implied volatility data, we have based our estimate of expected volatility primarily on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its stock-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon Income Taxes The Company provides for income taxes using the asset and liability method. The Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax assets to the amount that will more likely than not be realized. The Company does not have any material uncertain tax positions for which reserves would be required. The Company will recognize interest and penalties related to uncertain tax positions, if any, in income tax expense. Net Loss Per Share Basic net loss per share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, warrants to purchase common stock and stock options are considered to be common stock equivalents, but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented. Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are generally adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. The JOBS Act permits an emerging growth company such as the Company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that it either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. Accounting Standards Issued, Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments 2016-13”). 2016-13 held-to-maturity No. 2019-10, Financial Instruments — Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates 2016-13, In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options 470-20) Derivatives and Hedging – Contracts in Entity’s Own Equity 815-40) 2020-06”). 2020-06 2020-06 if-converted 2020-06

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Balance Sheet Information	3. Supplemental Balance Sheet Information Accrued expenses and other current liabilities consist of the following: December 31, 2022 December 31, 2021 Accrued consulting $ 232,390 $ 210,000 Accrued compensation 459,997 421,734 Accrued research and development 1,696,129 2,077,932 Accrued interest — 968 Accrued other 9,920 5,127 Total accrued expenses and other current liabilities $ 2,398,436 $ 2,715,761

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	4. Fair Value of Financial Instruments The following table summarizes cash equivalents and marketable securities measured at their fair value on a recurring basis as of December 31, 2022: Fair Value Measurements as of December 31, 2022 Using: Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 5,304,405 $ — $ — $ 5,304,405 Total $ 5,304,405 $ — $ — $ 5,304,405 Marketable securities, available-for-sale: U.S. treasury obligations $ 15,861,620 $ — $ — $ 15,861,620 Total $ 15,861,620 $ — $ — $ 15,861,620 There were no marketable securities as of December 31, 2021.

Marketable Securities

Marketable Securities	12 Months Ended
	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	5. Marketable Securities Marketable securities consisted of the following at December 31, 2022. December 31, 2022 Amortized Cost Unrealized Gain Unrealized Loss Fair Marketable securities, available-for-sale: U.S. treasury obligations $ 15,756,902 $ 104,718 $ — $ 15,861,620 Total $ 15,756,902 $ 104,718 $ — $ 15,861,620 As of December 31, 2022, the Company held three U.S. Treasury debt securities that were in an unrealized gain position totaling $104,718. There were no marketable securities as of December 31, 2021. The Company received proceeds of $4.96 million from maturities of marketable securities for the year ended December 31, 2022. The Company did not realize any gains or losses from maturities of marketable securities for the year ended December 31, 2022. There were no marketable securities as of December 31, 2021.

Equipment and Improvements

Equipment and Improvements	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Equipment and Improvements	6. Equipment and Improvements Equipment and Improvements, net December 31, 2022 Furniture and office equipment $ 72,692 Lab equipment 153,668 IT equipment 16,895 243,255 Less: accumulated depreciation 6,723 Total $ 236,532 Depreciation expense for the year ended December 31, 2022 was $6,723. There were no equipment and improvements as of December 31, 2021.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Notes Payable	7. Notes Payable Note Payable to CEO On February 5, 2020 (the “Issue Date”), the Company issued a note payable to its CEO (the “CEO Note”) in the face amount of $245,250 bearing 1.59% APR simple interest in exchange for cash. The net proceeds of $245,250 were used as working capital by the Company. The note carried an original maturity of the earlier of the sixth month following the Issue Date or the date the Company has sufficient funds to repay the CEO Note. If an event of default occurred and continued the Company agreed to issue a warrant to the holder with a strike price of $4.87 per share for a number of shares equal to 150% of the value of the loan. The Company assessed the terms and features of the CEO Note and determined that none of the terms and features represented embedded derivatives that require bifurcation. On June 13, 2020, the holder of the CEO Note and the Company entered into a restated agreement (the “CEO Restated Note”). The CEO Restated Note in the amount of $248,911 extended the stated maturity date of the CEO Note from the earlier of the sixth month following the (original) Issue Date or the date the Company has sufficient funds to repay the note to the earlier of the 30th month following the (original) Issue Date or the date the Company had sufficient funds to repay the CEO Restated Note. The Issue Date, February 5, 2020, is unchanged. In addition, the interest rate was reduced, effective as of the Issue Date, from 1.59% APR to 0.25%. The CEO Restated Note also changed the exercise price of the warrant from $4.87 to $4.81 per share in the case of any default. The other provisions of the CEO Restated Note remained the same, in all material respects, to the CEO Note. The Company and its CEO have agreed that the CEO Restated Note will not be repaid for a minimum of 12 months following the closing of its initial public offering. The principal balance of the CEO note was $248,911 at December 31, 2021. The principal balance plus accrued and unpaid interest on the CEO Note were settled in full, without adjustment, in cash on January 3, 2022.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Equity	8. Stockholders’ Equity Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding. As of December 31, 2022, a total 5,956,282 shares of common stock were reserved for issuance upon the exercise of outstanding stock options and warrants under the 2020 Equity Incentive Plan and the 2011 Equity Incentive Plan. Share Issuances In March 2021, an accredited investor subscribed for, and the Company issued, 9,000 shares of its stock in exchange for consulting services. The fair value of the stock was $60,391 based upon the closing price of the shares on the date of the transaction. Issuance costs were not material. No additional rights or options were granted to this accredited investor in connection with this issuance. In May 2021, the Company issued 73,496 shares of its common stock in connection with the exercise of 90,415 non-qualified In August 2021, the Company issued 21,853 shares of its common stock in connection with the exercise of non-qualified In connection with the June 2021 Offering, the Company issued and sold 15,000,000 fully paid non-assessable In January 2022, the Company issued 21,853 shares of its common stock in connection with the exercise of non-qualified In February 2022, a corporate accredited investor subscribed for, and the Company issued, 50,000 shares of its common stock in exchange for consulting services. The fair value of the common stock was $67,000 based upon the closing price of the shares on the date of the transaction. Issuance costs were not material. No additional rights or options were granted to this accredited investor in connection with this issuance. This issuance was exempt from registration pursuant to Section 4(a)(2) of the Securities Act as transactions by an issuer not involving any public offering.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	9. Stock-Based Compensation 2020 Equity Incentive Plan On July 21, 2020, the Company’s board of directors and its stockholders approved the 2020 Equity Incentive Plan (the “2020 Plan”). The 2020 Plan became effective immediately prior to the closing of the Company’s December 2020 IPO. The 2020 Plan provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock or restricted stock units to any of its employees, directors, consultants and other service providers or those of its affiliates. The board of directors has initially designated the compensation committee to administer the 2020 Plan. The compensation committee has broad authority to administer the plan and to determine the vesting conditions for awards. Neither the compensation committee nor the board of directors are authorized to reprice outstanding options or stock appreciation rights without shareholder consent. In addition, any amendments to increase the total number of shares reserved for issuance under the 2020 Plan or modification of the classes of participants eligible to awards requires ratification by the stockholders. Subject to certain adjustments, the maximum number of shares of common stock that may be issued under the 2020 Plan in connection with awards is limited to 8,650,000 shares. Following the effectiveness of the 2020 Plan, the Company ceased making grants under the 2011 Plan. However, the 2011 Plan continues to govern the terms and conditions of the outstanding awards granted under the 2011 Plan. Shares of common stock subject to awards granted under the 2011 Plan that cease to be subject to such awards by forfeiture or otherwise after the effective date of the 2020 Plan will become available for issuance under the 2020 Plan. 2011 Equity Incentive Plan Prior to the closing of its IPO, the Company maintained the 2011 Plan, pursuant to which the Company made grants of non-qualified Stock Options During the years ended December 31, 2022 and 2021, the Company granted options with an aggregate fair value of $536,965 and $484,669, respectively, which are being amortized to expense over the vesting period of the options as the services are being provided. The following is a summary of option activity under the 2011 Plan and the 2020 Plan: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Term (In Years) Outstanding at December 31, 2020 3,596,444 $ 2.27 7.73 Granted 215,898 3.88 — Exercised (112,268 ) 0.70 — Forfeited (40,708 ) 0.38 — Cancelled — — — Outstanding at December 31, 2021 3,659,366 2.43 6.99 Granted 869,887 1.00 — Exercised (21,854 ) 2.02 — Forfeited (113,030 ) 1.28 — Cancelled — — — Outstanding at December 31, 2022 4,394,369 2.19 6.20 Exercisable at December 31, 2022 3,497,813 2.33 1.64 As of December 31, 2022, the intrinsic value of options outstanding was $0.3 million and 100% of the intrinsic value of options was exercisable. Intrinsic value is calculated based on the aggregate difference between the closing price of the Company’s common stock on the last trading day of 2022 and the exercise price of each in the money stock option award. There were no options to purchase stock that vest ed The weighted-average fair values of options granted in the years ended December 31, 2022 and 2021 were $0.64 and $2.24, per share, respectively, and were calculated using the following estimated assumptions: Year ended December 31, 2022 2021 Weighted-average risk-free interest rate 2.17 % 0.59 % Expected dividend yield 0.00 % 0.00 % Expected volatility 84.88 % 82.22 % Expected terms 4.39 years 3.97 years The total fair values of stock options that vested during the years ended December 31, 2022 and 2021 were $618,157 and $1,150,320, respectively. As of December 31, 2022, there was $196,977 of total unrecognized compensation cost related to non-vested Restricted Stock Units During the years ended December 31, 2022 and 2021, there were no restricted stock units issued or outstanding. Stock-Based Compensation Expense The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees: Year ended December 31, 2022 2021 Research and development $ 120,671 $ 665,834 Selling, general and administrative 337,476 866,042 Total stock-based compensation expense $ 458,147 $ 1,531,876

ATM Program

ATM Program	12 Months Ended
	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
ATM Program	10. ATM Program On May 16, 2022, the Company entered into an Equity Distribution Agreement (the “Agreement”) with Piper Sandler & Co. as sales agent (the “Agent”), pursuant to which the Company may, from time to time, issue and sell shares of its common stock, at an aggregate offering price of up to $9.8 million (the “Shares”) through the Agent. Under the terms of the Agreement, the Agent may sell the Shares at market prices by any method that is deemed to be an “ATM” as defined in Rule 415 under the Securities Act, as amended. Subject to the terms and conditions of the Agreement, the Agent will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company’s instructions. The Company has no obligation to sell any of the Shares, and may at any time suspend sales under the Agreement or terminate the Agreement in accordance with its terms. The Company has provided the Agent with customary indemnification rights, and the Agent will be entitled to a fixed commission of 3.0% of the aggregate gross proceeds from the Shares sold. The Agreement contains customary representations and warranties, and the Company is required to deliver customary closing documents and certificates in connection with sales of the Shares. As of December 31, 2022, no Shares have been sold under the Agreement. Effective January 25, 2023, the Company terminated the Equity Distribution Agreement by providing a notice of termination to the Agent in accordance with the terms of the Equity Distribution Agreement.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2022
Warrants and Rights Note Disclosure [Abstract]
Warrants	11. Warrants Kubera North America, Inc. (“Kubera”), in connection with consulting services, was granted a warrant in October 2018 to purchase 4.9% of our issued and outstanding shares of common stock at the time of issuance of the warrant, or 400,866 shares. Kubera warrants became fully vested on October 27, 2021. The warrant has a term of 7 years, is exercisable at $4.79 per share post reverse split. On June 24, 2020 the Kubera warrant was transferred to Kubera N.A. LLC, an affiliate of Kubera. On January 1, 2019, the Company issued a seven-year warrant to a service provider to purchase 20,533 shares of the Company’s common stock with an exercise price of $4.79 per share. The warrants vested immediately. The Company received legal services, as needed, during 2019 under an unwritten agreement with the service provider. The warrants are classified within stockholders’ equity at their fair value and were treated as a standalone instrument. The fair value of the warrant was determined to be $82,141 utilizing the Black-Scholes-Merton On March 31, 2020, the Company issued a warrant to purchase up to 26,225 shares of its stock to one of its consultants in exchange for legal services, as needed, during 2020. The warrant contains a strike price of $5.67 per share and has a seven-year contractual term. The warrant is classified within stockholders’ deficit at its fair value and was treated as a standalone instrument. The grant date fair value of the warrant was determined to be $101,478 utilizing the Black-Scholes-Merton option-pricing model at the time of issuance and is all included in selling, general and administrative expenses for the year ended December 31, 2020. On August 25, 2020, the Company granted a fully vested warrant to purchase up to 21,854 shares of its common stock to Flagship Consulting, Inc. in connection with consulting services provided to the Company. The warrant is exercisable at a strike price of $5.90 per share and has a contractual term of seven years. The warrant is classified within stockholders’ equity at its fair value as a standalone instrument. The grant date fair value of the warrant was determined to be $87,597 utilizing the Black-Scholes-Merton option-pricing model at the time of issuance and is included in selling, general and administrative expenses for the year ended December 31, 2020. On August 25, 2020, the Company granted a warrant to purchase up to 150,000 shares of its common stock to Flagship Consulting, Inc. in connection with consulting services to be provided to the Company. The warrant is exercisable at a strike price of $5.90 per share and has a contractual term of seven years. The warrant vests in full and becomes exercisable on the first anniversary of the grant date. The warrant is classified within stockholders’ equity at its fair value as a standalone instrument over the vesting period. The aggregate grant date fair value of the warrant was determined to be $601,245 utilizing the Black-Scholes-Merton option-pricing model at the time of issuance and will be included in selling, general and administrative expenses as services are rendered during its 12-month On December 28, 2020, the Company issued a ten-year Black-Scholes-Merton The Company issued and sold to its underwriters warrants to purchase up to 90,000 shares of its common stock and up to 750,000 shares of its common stock in connection with its December 2020 IPO and its June 2021 Offering, respectively. The warrants were sold for an aggregate purchase price of $100 for each set of warrants and have five-year terms. The IPO warrant is exercisable beginning June 20, 2021 at an initial exercise price of $12.50 per share of common stock. The June 2021 Offering warrant is exercisable beginning June 15, 2022 at an initial exercise price of $3.75 per share of common stock. No warrants were exercised for the year ended December 31, 2022 or 2021.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	12. Net Loss Per Share The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders: Year ended December 31, 2022 2021 Numerator: Net loss $ (18,054,155 ) $ (14,786,063 ) Denominator: Weighted-average number of common shares 25,211,726 18,209,198 Net loss per share applicable to common $ (0.72 ) $ (0.81 ) The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented: Year ended December 31, 2022 2021 Options to purchase shares of stock 4,394,369 3,596,444 Warrants to purchase shares of stock 1,561,913 1,561,913 Total 5,956,282 5,158,357

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Tax	13. Income Taxes No provision or benefit for federal or state income taxes has been recorded, as the Company has incurred a net loss for all of the periods presented, and the Company has provided a full valuation allowance against its deferred tax assets. At December 31, 2022, the Company had federal net operating loss carryforwards of approximately $1.6 million which will begin to expire in varying amounts annually beginning in 2030 and $24.5 million of federal net operating losses with no expiration. At December 31, 2022, the Company had state net operating loss carryforwards of approximately $24.4 million which will begin to expire in varying amounts annually beginning in 2030. Utilization of net operating losses may be subject to substantial annual limitations due to the “change in ownership” provisions of the Internal Revenue Code, and similar state provisions. The annual limitations may result in the expiration of net operating losses before utilization. The Company has not yet conducted a study to determine if any such changes, including its 2020 IPO or 2021 underwritten public offering, have occurred that could limit the Company’s ability to use the net operating losses and tax credit carryforwards. The reconciliation of the U.S. federal statutory rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2022 2021 Tax at statutory rate 21.00 % 21.00 % State income taxes 6.17 % 4.89 % Stock-based compensation — (0.13 )% Other 0.03 % 0.02 % Change in valuation allowance (27.20 )% (25.78 )% Effective tax rate 0.00 % 0.00 % The significant components of the Company’s deferred tax assets consist of the following at December 31, 2022 and 2021: December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 6,890,275 $ 5,202,047 Capitalized research and development 2,854,530 — Stock-based compensation 2,440,885 2,272,970 Accrued expenses 199,961 — Total deferred tax assets 12,385,651 7,475,017 Deferred tax asset valuation allowance (12,385,651 ) (7,475,017 ) Net deferred tax asset $ — $ — The Company has maintained a full valuation allowance against its deferred tax assets in all periods presented. A valuation allowance is required to be recorded when it is not more likely than not that some portion or all of the net deferred tax assets will be realized. Since the Company cannot determine that it is more likely than not that it will generate taxable income, and thereby realize the net deferred tax assets, a full valuation allowance has been provided. The valuation allowance increased $4.9 million and $3.8 million for the years ended December 31, 2022 and 2021, respectively. The increases in 2022 and 2021 are primarily related to each year’s taxable loss. The Company has no uncertain tax positions at December 31, 2022 and 2021 that would affect its effective tax rate. Since the Company is in a loss carryforward position, the Company is generally subject to U.S. federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. The Tax Cuts and Jobs Act (“TCJA”) resulted in significant changes to the treatment of research and developmental (R&D) expenditures under Section 174. For tax years beginning after Dec. 31, 2021, taxpayers are required to capitalize and amortize all R&D expenditures that are paid or incurred in connection with their trade or business. Specifically, costs for U.S.-based R&D activities must be amortized over five years and costs for foreign R&D activities must be amortized over 15 years—both using a midyear convention. During the year ended December 31, 2022, the Company capitalized $9.8 million and $2.0 million of domestic and foreign R&D expenses, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies Impact of the COVID-19 The COVID-19 COVID-19, shelter-in-place COVID-19 COVID-19 As a result of the COVID-19 COVID-19 shelter-in-place follow-up COVID-19 COVID-19 COVID-19 Although the Company did not experience a material impact on its operations during the year ended December 31, 2022 or December 2021, the Company notes the high level of difficulty in determining the future potential adverse financial impact and other effects of COVID-19 Operating Leases On April 18, 2022, the Company entered into an operating lease agreement for office space at its new location in Lexington, Massachusetts (the “Office Lease”). On August 8, 2022, the Company commenced occupancy of the leased space. The lease runs through September 30, 2025 or a remaining lease period of 2.5 years. We have an option to extend the lease term for an additional three (3) years thereafter. The Company accounts for the Office Lease under the provisions of ASU No. 2021-09, 2018-10, right-of-use right-of-use non-current The Office Lease contains escalating payments during the lease period. Upon execution of the Office Lease, the Company prepaid one month of rent and a security deposit, one of which will be held in escrow and credited at the termination of the lease and the other of which will be applied to the first month’s rent. As of December 31, 2022, a security deposit of approximately $25,000 was included in prepaid expenses and other current assets on the Company’s consolidated balance sheets related to the Office Lease. Future minimum lease payments under these leases at December 31, 2022, are presented by calendar year as follows:. Year 2023 $ 145,836 2024 150,095 2025 114,966 Total lease payments 410,897 Less: imputed interest (59,609 ) Present value of operating lease liabilities $ 351,288 Guarantees As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is for the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ insurance coverage that limits its exposure and enables it to recover a portion of any future amounts paid. The Company leases office space on a month-to-month In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company’s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements. As of December 31, 2022, and 2021, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established. License Agreements Emory University License Agreements On June 8, 2010, the Company entered into two license agreements with Emory University, the first for which the Company granted to Emory 393,370 shares of its common stock (“License A”), and the second for which the Company granted to Emory 437,078 shares of its common stock (“License B”). The Company recorded $313,500 which represented the fair value of the shares issued as part of the total consideration to Emory for the licenses. The fair value of the shares was determined to be more reliably measurable than the fair value of the consideration received. In exchange, Emory granted the Company and its affiliates an exclusive worldwide sublicensable right and license to practice under certain patent rights and technology to make, have, develop, promote, market, import, export, distribute, offer for sale, sell and otherwise use the licensed products in the field of use anywhere in the world. Unless sooner terminated as provided elsewhere in the agreement, the License A term is the later of 10 years or until the expiration of the patent rights. License B was terminated in May 2013 under the normal course of business. No shares were forfeited or returned and are still owned by Emory. The Company is required to pay royalties on net sale of products and processes that are covered by the patent rights licensed under the agreement at a percentage in the low single digits, subject to reductions and offsets in certain circumstances, as well as a royalty on net sales of products that the Company sublicenses ranging from low single digit to low double digit percentages based upon stage of development. The Company is obligated to pay potential total milestone payments of $280,000 based upon achievement of certain stages of development. During the years ended December 31, 2022 and 2021, the Company did not incur any milestone fees. Sphaera Pharma Pte. Ltd. On March 2, 2012, the Company entered into a collaborative research and development agreement, or the Sphaera Agreement with Sphaera Pharma Pte. Ltd., or Sphaera, to collaborate on the development of the prodrug technology to be applied to protein kinase inhibitors for oncology and non-oncology pre-existing non-filing The prosecution of patents related to the Company Compounds, which includes the prodrug technology, is the responsibility of the Company. As consideration for its services, Sphaera has received a fixed fee of $160,000 and is entitled to the following milestone payments upon achievement of specified milestones: Milestone Event Payment First dosing of patient in US Phase 1 trial $ 250,000 US Phase 1 trial completion with endpoints met 500,000 US Phase 2 trial completion with endpoints met 875,000 FDA Approval 4,000,000 Total potential milestone payments $ 5,625,000 No milestones have been achieved and, as such, no milestone payments have been made to Sphaera, and the Company does not consider probable that any milestones will be achieved within the next twelve months. Sphaera is also entitled to royalty payments of a percentage of annual net sales and sublicenses ranging in the mid-single The prosecution of patents related to the Company Compounds, which includes the prodrug technology, is the responsibility of the Company. The parties did not contemplate the development of IkT-001Pro re-negotiating Litigation From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability would include probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. We are not currently a party to any material litigation or legal proceedings.

Simple Retirement Account for E

Simple Retirement Account for Employees (the "Simple IRA")	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Simple Retirement Account for Employees (the "Simple IRA")	15. Simple Retirement Account for Employees (the “Simple IRA”) The Company established an individual retirement plan for employees effective January 1, 2013 under Section 408(p) of the Internal Revenue Code. The Simple IRA covers substantially all employees of the Company who received at least $5,000 in compensation from the Company during any two preceding years and are reasonably expected to receive at least $5,000 in compensation from the Company in the current year of participation. Subject to certain overall statutory limitations, the Company must match employee contributions up to 3% of employees’ qualified compensation for the year. Company contributions under the Simple IRA were $48,408 and $28,938 for the years ended December 31, 2022 and 2021, respectively.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events Concurrent Registered Direct Offering and Private Placements On January 25, 2023, the Company entered into a securities purchase agreement in connection with a registered direct offering and concurrent private placement with an institutional investor. The Company also entered into a securities purchase agreement and a registration rights agreement in connection with a concurrent private placement with the same institutional investor (the “January 2023 Offering”). The January 2023 Offering consisted of (i) 2,800,789 shares of Common Stock sold at $0.86 per share, (ii) Common Warrants to purchase up to 11,627,908 shares of Common Stock with an exercise price of $0.86, and (iii) Pre-Funded Master Fund Ltd (“Armistice”). The Common Warrants will expire on January 27, 2028. As part of the January 2023 Offering the company further issued H.C. Wainwright & Co., LLC (“Placement Agent Warrants”) to purchase up to 406,977 shares of Common Stock with an exercise price of $1.075 and an expiration date of January 25, 2028. As of March 28, 2023, Armistice has exercised 3,028,398 warrants. The Company received net proceeds from the January 2023 Offering of approximately $8.7 million. Effective January 25, 2023, the Company terminated the Equity Distribution Agreement by providing a notice of termination to the Agent in accordance with the terms of the Equity Distribution Agreement.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements for the years ended December 31, 2022 and 2021, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for financial information, which prescribes elimination of all significant inter-company accounts and transactions in the accounts of the Company and its wholly owned subsidiary, IKT Securities Corporation, which was incorporated in the Commonwealth of Massachusetts in December 2021. In the opinion of management, these consolidated financial statements reflect all adjustments which are necessary for a fair statement of the Company’s financial position and results of its operations, as of and for the periods presented. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Consolidation	Consolidation The accompanying consolidated financial statements include the Company and its wholly owned subsidiary, IKT Securities Corporation. The Company has eliminated all inter-company transactions for the years presented.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company utilizes certain estimates in the determination of our liquidity and working capital adequacy, the fair value of its stock options and warrants, deferred tax valuation allowances and revenue recognition, to record expenses relating to research and development contracts and accrued expenses. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates.
Off-Balance Sheet Risk and Concentrations of Credit Risk	Off-Balance The Company has no significant off-balance The Company has not experienced any losses in such accounts and management believes that the Company does not have significant credit risk with respect to such cash and cash equivalents and marketable securities. For the years ended December 31, 2022 and 2021, the Company derived 100% of its total revenue from a single source, the United States Government, in the form of federal research grants.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments that are readily convertible to known amounts of cash with original maturities of three months or less at date of purchase to be cash equivalents. The Company had cash and cash equivalents of $
Accounts receivable	Accounts receivable The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding invoices and the overall quality and age of those invoices. To date, the Company has no write-offs no
Leases	Leases The Company accounts for its leases under ASU 2021-09, 2018-10, Leases right-of-use Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any of these criteria. For all leases at the lease commencement date, a right-of-use right-of-use The right-of-use right-of-use Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease cost for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease cost are any variable lease payments incurred in the period that are not included in the initial lease liability and lease payments incurred in the period for any leases with an initial term of 12 months or less. Lease cost for finance leases consists of the amortization of the right-of-use The Company has made an accounting policy election to not recognize leases with an initial term of 12 months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis in our consolidated statements of operations and comprehensive loss over the lease term.
Equipment and Improvements	Equipment and Improvements Equipment and improvements are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated usefulness from three to five years for network equipment, office equipment, and furniture classified as fixed assets. Estimated Useful Economic Life Leasehold property improvements, right of use assets Lesser of lease term or useful life Furniture and office equipment 5 years Lab equipment 3 Years IT equipment 3 years
Fair Value Measurements	Fair Value Measurements The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements. • Level 1 — Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access; • Level 2 — Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates; and • Level 3 — Inputs are unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services. The pricing services utilize industry standard valuation models, including both
Marketable Securities	Marketable Securities The Company’s marketable securities consist of U.S. Treasury securities with maturities of less than one year which are classified as available-for-sale Available-for-sale Available-for-sale
Revenue Recognition	Revenue Recognition The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange Revenue from Contracts with Customers
Research and Development Costs	Research and Development Costs Costs incurred in the research and development of the Company’s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with performing services under grant revenue contracts and include salaries and benefits, stock compensation, research-related subcontractors and consultants, supplies and overhead costs. Advance payments made to suppliers and contract research organizations are classified as prepaid research and development and are expensed as research and development as the supplies are consumed and the contract services are provided.
Stock-Based Compensation	Stock-Based Compensation The Company has a stock-based compensation plan which is more fully described in Note 9. The Company records stock-based compensation for options granted to employees and to members of the board of directors for their services on the board of directors, based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the applicable service period, which is generally one to two years. The Company accounts for non-employee non-employee The Company uses the Black-Scholes-Merton option-pricing model to determine the fair value of stock options. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company has concluded that the historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of Company specific historical and implied volatility data, we have based our estimate of expected volatility primarily on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics are selected, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its stock-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon
Income Taxes	Income Taxes The Company provides for income taxes using the asset and liability method. The Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax assets to the amount that will more likely than not be realized. The Company does not have any material uncertain tax positions for which reserves would be required. The Company will recognize interest and penalties related to uncertain tax positions, if any, in income tax expense.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, warrants to purchase common stock and stock options are considered to be common stock equivalents, but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented.
Recent Accounting Standards	Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are generally adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. The JOBS Act permits an emerging growth company such as the Company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that it either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. Accounting Standards Issued, Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments 2016-13”). 2016-13 held-to-maturity No. 2019-10, Financial Instruments — Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates 2016-13, In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options 470-20) Derivatives and Hedging – Contracts in Entity’s Own Equity 815-40) 2020-06”). 2020-06 2020-06 if-converted 2020-06

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of accrued expenses and other current liabilitiies	Accrued expenses and other current liabilities consist of the following: December 31, 2022 December 31, 2021 Accrued consulting $ 232,390 $ 210,000 Accrued compensation 459,997 421,734 Accrued research and development 1,696,129 2,077,932 Accrued interest — 968 Accrued other 9,920 5,127 Total accrued expenses and other current liabilities $ 2,398,436 $ 2,715,761

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Summery of Fair Value Assets Measured On Recurring Basis	The following table summarizes cash equivalents and marketable securities measured at their fair value on a recurring basis as of December 31, 2022: Fair Value Measurements as of December 31, 2022 Using: Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 5,304,405 $ — $ — $ 5,304,405 Total $ 5,304,405 $ — $ — $ 5,304,405 Marketable securities, available-for-sale: U.S. treasury obligations $ 15,861,620 $ — $ — $ 15,861,620 Total $ 15,861,620 $ — $ — $ 15,861,620

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Marketable securities consisted of the following at December 31, 2022. December 31, 2022 Amortized Cost Unrealized Gain Unrealized Loss Fair Marketable securities, available-for-sale: U.S. treasury obligations $ 15,756,902 $ 104,718 $ — $ 15,861,620 Total $ 15,756,902 $ 104,718 $ — $ 15,861,620

Equipment and Improvements (Tab

Equipment and Improvements (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule Of Equipment and Improvements, net	Equipment and Improvements, net December 31, 2022 Furniture and office equipment $ 72,692 Lab equipment 153,668 IT equipment 16,895 243,255 Less: accumulated depreciation 6,723 Total $ 236,532

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Option Activity Under 2011 Plan and 2020 Plan	The following is a summary of option activity under the 2011 Plan and the 2020 Plan: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Term (In Years) Outstanding at December 31, 2020 3,596,444 $ 2.27 7.73 Granted 215,898 3.88 — Exercised (112,268 ) 0.70 — Forfeited (40,708 ) 0.38 — Cancelled — — — Outstanding at December 31, 2021 3,659,366 2.43 6.99 Granted 869,887 1.00 — Exercised (21,854 ) 2.02 — Forfeited (113,030 ) 1.28 — Cancelled — — — Outstanding at December 31, 2022 4,394,369 2.19 6.20 Exercisable at December 31, 2022 3,497,813 2.33 1.64
Schedule of Estimated Assumptions of Weighted-Average Fair Values of Options Granted	The weighted-average fair values of options granted in the years ended December 31, 2022 and 2021 were $0.64 and $2.24, per share, respectively, and were calculated using the following estimated assumptions: Year ended December 31, 2022 2021 Weighted-average risk-free interest rate 2.17 % 0.59 % Expected dividend yield 0.00 % 0.00 % Expected volatility 84.88 % 82.22 % Expected terms 4.39 years 3.97 years
Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees	The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees: Year ended December 31, 2022 2021 Research and development $ 120,671 $ 665,834 Selling, general and administrative 337,476 866,042 Total stock-based compensation expense $ 458,147 $ 1,531,876

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders	The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders: Year ended December 31, 2022 2021 Numerator: Net loss $ (18,054,155 ) $ (14,786,063 ) Denominator: Weighted-average number of common shares 25,211,726 18,209,198 Net loss per share applicable to common $ (0.72 ) $ (0.81 )
Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders	The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented: Year ended December 31, 2022 2021 Options to purchase shares of stock 4,394,369 3,596,444 Warrants to purchase shares of stock 1,561,913 1,561,913 Total 5,956,282 5,158,357

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Reconciliation of Effective Income Tax Rate	The reconciliation of the U.S. federal statutory rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2022 2021 Tax at statutory rate 21.00 % 21.00 % State income taxes 6.17 % 4.89 % Stock-based compensation — (0.13 )% Other 0.03 % 0.02 % Change in valuation allowance (27.20 )% (25.78 )% Effective tax rate 0.00 % 0.00 %
Components of Deferred Tax Assets and Liabilities	The significant components of the Company’s deferred tax assets consist of the following at December 31, 2022 and 2021: December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 6,890,275 $ 5,202,047 Capitalized research and development 2,854,530 — Stock-based compensation 2,440,885 2,272,970 Accrued expenses 199,961 — Total deferred tax assets 12,385,651 7,475,017 Deferred tax asset valuation allowance (12,385,651 ) (7,475,017 ) Net deferred tax asset $ — $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Future minimum lease payments under these leases at December 31, 2022, are presented by calendar year as follows:. Year 2023 $ 145,836 2024 150,095 2025 114,966 Total lease payments 410,897 Less: imputed interest (59,609 ) Present value of operating lease liabilities $ 351,288
Schedule of Milestone Payment	As consideration for its services, Sphaera has received a fixed fee of $160,000 and is entitled to the following milestone payments upon achievement of specified milestones: Milestone Event Payment First dosing of patient in US Phase 1 trial $ 250,000 US Phase 1 trial completion with endpoints met 500,000 US Phase 2 trial completion with endpoints met 875,000 FDA Approval 4,000,000 Total potential milestone payments $ 5,625,000

Nature of Business - Additional

Nature of Business - Additional Information (Details) - USD ($)	Jan. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Organization Consolidation And Presentation [Line Items]
Working capital		$ 20,675,677
Accumulated deficit		(47,871,842)	$ (29,817,687)
Cash		7,188,553
Marketable securities		15,861,620	$ 0
Accounts payable and accrued expenses		$ 3,549,609
IPO
Organization Consolidation And Presentation [Line Items]
Working capital					$ 14,600,000
June 2021 Offering
Organization Consolidation And Presentation [Line Items]
Working capital				$ 41,100,000
January 2023 Offering | Subsequent Event [Member]
Organization Consolidation And Presentation [Line Items]
Working capital	$ 8,700,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents	$ 7,188,553	$ 40,750,133
Accounts receivable, allowance for credit loss	$ 0	$ 0
Computer Equipment [Member] | Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated Useful Lives	three
Office Equipment [Member] | Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated Useful Lives	five

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Equipment and Improvements (Details)	12 Months Ended
	Dec. 31, 2022
Leasehold property improvements, right of use assets
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	Lesser of lease term or useful life
Furniture and office equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Economical Life	5 years
Lab equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Economical Life	3 years
IT equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Economical Life	3 years

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued consulting	$ 232,390	$ 210,000
Accrued compensation	459,997	421,734
Accrued research and development	1,696,129	2,077,932
Accrued interest	0	968
Accrued other	9,920	5,127
Total accrued expenses and other current liabilities	$ 2,398,436	$ 2,715,761

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Cash Equivalents And Marketable Securities Measured At Their Fair Value On A Recurring Basis (Details)	Dec. 31, 2022 USD ($)
Cash and Cash Equivalents [Line Items]
Marketable securities, Amortized cost	$ 15,756,902
Fair Value, Recurring [Member]
Cash and Cash Equivalents [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	5,304,405
Marketable securities, Amortized cost	15,861,620
U.S. Treasury obligations | Fair Value, Recurring [Member]
Cash and Cash Equivalents [Line Items]
Marketable securities, Amortized cost	15,861,620
Money market funds | Fair Value, Recurring [Member]
Cash and Cash Equivalents [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	5,304,405
Level 1 | Fair Value, Recurring [Member]
Cash and Cash Equivalents [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	5,304,405
Marketable securities, Amortized cost	15,861,620
Level 1 | U.S. Treasury obligations | Fair Value, Recurring [Member]
Cash and Cash Equivalents [Line Items]
Marketable securities, Amortized cost	15,861,620
Level 1 | Money market funds | Fair Value, Recurring [Member]
Cash and Cash Equivalents [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	5,304,405
Level 2 | Fair Value, Recurring [Member]
Cash and Cash Equivalents [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	0
Marketable securities, Amortized cost	0
Level 2 | U.S. Treasury obligations | Fair Value, Recurring [Member]
Cash and Cash Equivalents [Line Items]
Marketable securities, Amortized cost	0
Level 2 | Money market funds | Fair Value, Recurring [Member]
Cash and Cash Equivalents [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	0
Level 3 | Fair Value, Recurring [Member]
Cash and Cash Equivalents [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	0
Marketable securities, Amortized cost	0
Level 3 | U.S. Treasury obligations | Fair Value, Recurring [Member]
Cash and Cash Equivalents [Line Items]
Marketable securities, Amortized cost	0
Level 3 | Money market funds | Fair Value, Recurring [Member]
Cash and Cash Equivalents [Line Items]
Cash equivalents and marketable securities measured at their fair value on a recurring basis	$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Additional Information (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Marketable securities	$ 15,861,620	$ 0

Marketable Securities - Summary

Marketable Securities - Summary of Marketable Securities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Marketable securities, available-for-sale:
Marketable securities, Amortized cost	$ 15,756,902
Marketable securities, Unrealized Gain	104,718
Marketable securities, Unrealized Loss	0	$ 0
Marketable securities, Fair Value	15,861,620	$ 0
U.S. treasury obligations
Marketable securities, available-for-sale:
Marketable securities, Amortized cost	15,756,902
Marketable securities, Unrealized Gain	104,718
Marketable securities, Unrealized Loss	0
Marketable securities, Fair Value	$ 15,861,620

Marketable Securities - Additio

Marketable Securities - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Marketable securities, available-for-sale:
Marketable securities, Unrealized Loss	$ 0	$ 0
Proceeds from Sale and Maturity of Marketable Securities	4.96
US Treasury Securities [Member]
Marketable securities, available-for-sale:
Marketable securities, Unrealized Loss	$ 104,718

Equipment and Improvements - Sc

Equipment and Improvements - Schedule of Equipment and Improvements, Net (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 243,255
Less: Accumulated Depreciation	6,723
Property, Plant and Equipment, Net, Total	236,532	$ 0
Furniture and office equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	72,692
Lab equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	153,668
IT equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 16,895

Equipment and Improvements - Ad

Equipment and Improvements - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Equipment and improvements, net	$ 236,532	$ 0
Depreciation	$ 6,723	$ 0

Notes Payable - Additional Info

Notes Payable - Additional Information (Details) - USD ($)		12 Months Ended
	Feb. 05, 2020	Dec. 31, 2022	Dec. 31, 2021	Oct. 27, 2021	Dec. 28, 2020	Aug. 25, 2020	Jun. 13, 2020	Mar. 31, 2020	Jan. 01, 2019
Debt Instrument [Line Items]
Annual interest rate	1.59%
Strike price	$ 4.87			$ 4.79	$ 10	$ 5.9		$ 5.67	$ 4.79
Issue date	Feb. 05, 2020
Principal Balance
Debt Instrument [Line Items]
Notes payable, net of current portion			$ 248,911
CEO Note
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 245,250
Annual interest rate	1.59%
Net proceeds	$ 245,250
Maturity description		The note carried an original maturity of the earlier of the sixth month following the Issue Date or the date the Company has sufficient funds to repay the CEO Note.
On event of default		If an event of default occurred and continued the Company agreed to issue a warrant to the holder with a strike price of $4.87 per share for a number of shares equal to 150% of the value of the loan.
Strike price	$ 4.87
Percentage of number of shares to value of loan	150%
CEO Restated Note
Debt Instrument [Line Items]
Debt Instrument, Face Amount							$ 248,911
Annual interest rate							0.25%
Strike price							$ 4.81

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details)	1 Months Ended					6 Months Ended	12 Months Ended
	Feb. 28, 2022 USD ($) shares	Jan. 31, 2022 $ / shares shares	Aug. 31, 2021 $ / shares shares	May 31, 2021 $ / shares shares	Mar. 31, 2021 USD ($) shares	Jun. 30, 2021 USD ($) $ / shares shares	Dec. 31, 2022 Vote shares
Class Of Stock [Line Items]
Votes per each common stock share | Vote							1
Common stock shares reserved for issuance							5,956,282
Additional rights or options granted		0
Issuance of common stock, stock options exercised, Shares				90,415
Common stock in connection with exercise of non-qualified stock options, Shares		21,853	21,853	73,496
Common Stock In Connection With Exercise of Non Qualified Stock Options Shares Withheld for taxes.				16,919
Stock option strike price | $ / shares		$ 2.02	$ 2.02	$ 0.38
Consulting Services [Member]
Class Of Stock [Line Items]
Additional rights or options granted	0				0
Shares issued in exchange for consulting services	50,000				9,000
Fair value of stock issued in exchange for consulting services | $	$ 67,000				$ 60,391
June 2021 Offering
Class Of Stock [Line Items]
Shares issued price per share | $ / shares						$ 3
Proceeds from issuance of common stock | $						$ 41,100,000
Offering costs, underwriting discounts and commissions | $						$ 3,900,000
Issued and sold fully paid non-assessable shares of common stock						15,000,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | $	$ 300,000
Percentage of stock option exercised	100
Options, Grants in Period, Weighted Average Fair Value | $ / shares	$ 0.64	$ 2.24
Fair Values of Stock Options, Vested, Total | $	$ 618,157	$ 1,150,320
Number of options vest purchase | shares	0
2020 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant | shares	8,650,000
2011 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option, aggregate grant date fair value | $	$ 536,965	$ 484,669
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units outstanding | shares	0	0
2011 Plan and 2020 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation of unvested options | $	$ 196,977
Number of options vest purchase | shares	869,887	215,898
Expected to Recognize, Remaining Weighted-Average Period	1 year 7 months 20 days

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Option Activity Under 2011 Plan and 2020 Plan (Details) - $ / shares	1 Months Ended	12 Months Ended
	May 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Granted		0
Number of Shares, Exercised	(90,415)
2011 Plan and 2020 Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Outstanding, Beginning Balance		3,659,366	3,596,444
Number of Shares, Granted		869,887	215,898
Number of Shares, Exercised		(21,854)	(112,268)
Number of Shares, Forfeited		(113,030)	(40,708)
Number of Shares Outstanding, Ending Balance		4,394,369	3,659,366	3,596,444
Number of Shares, Exercisable		3,497,813
Weighted Average Exercise Price, Outstanding Beginning Balance		$ 2.43	$ 2.27
Weighted Average Exercise Price ,Granted		1	3.88
Exercised, weighted average exercise price (in dollars per share)		2.02	0.7
Forfeited, weighted average exercise price (in dollars per share)		1.28	0.38
Weighted Average Exercise Price, Outstanding Ending Balance		2.19	$ 2.43	$ 2.27
Weighted Average Exercise Price, Exercisable		$ 2.33
Weighted Average Remaining Contractual Term (In Years), Outstanding Beginning Balance		6 years 2 months 12 days	6 years 11 months 26 days	7 years 8 months 23 days
Weighted Average Remaining Contractual Term (In Years), Outstanding Ending Balance		6 years 2 months 12 days	6 years 11 months 26 days	7 years 8 months 23 days
Weighted Average Remaining Contractual Term (In Years), Exercisable		1 year 7 months 20 days

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Estimated Assumptions of Weighted-Average Fair Values of Options Granted (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Weighted-average risk-free interest rate	2.17%	0.59%
Expected dividend yield	0%	0%
Expected volatility	84.88%	82.22%
Expected terms	4 years 4 months 20 days	3 years 11 months 19 days

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 458,147	$ 1,531,876
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	120,671	665,834
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 337,476	$ 866,042

ATM Program - Additional Inform

ATM Program - Additional Information (Details) - Equity Distribution Agreement - USD ($) $ in Millions	May 16, 2022	Dec. 31, 2022
Marketable Securities [Line Items]
Common stock Aggregate offering price	$ 9.8
Fixed commission percentage		3%

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($)

1 Months Ended

12 Months Ended

Dec. 28, 2020

Aug. 25, 2020

Mar. 31, 2020

Jan. 01, 2019

Jun. 30, 2021

Dec. 31, 2020

Oct. 31, 2018

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Jun. 15, 2022

Oct. 27, 2021

Feb. 05, 2020

Class Of Warrant Or Right [Line Items]

Class of warrant or right issued, percentage

4.90%

Class of warrant or right issued

102,435

150,000

26,225

20,533

400,866

Contractual term

7 years

7 years

7 years

5 years

7 years

Strike price

$ 10

$ 5.9

$ 5.67

$ 4.79

$ 4.79

$ 4.87

Fair value of warrant

$ 101,478

$ 82,141

$ 685,441

$ 100

$ 685,441

Class of warrant or right vested

21,854

Warrant expense

$ 0

$ 688,784

Class of warrant or right exercised in period

0

0

Selling, general and administrative

$ 6,217,063

$ 6,507,641

First Anniversary Date Of Grant

Class Of Warrant Or Right [Line Items]

Fair value of warrant

$ 601,245

IPO

Class Of Warrant Or Right [Line Items]

Class of warrant or right issued

750,000

Strike price

$ 12.5

Class of warrant or right, date from which warrants or rights exercisable

Jun. 20, 2021

Underwriters

Class Of Warrant Or Right [Line Items]

Class of warrant or right issued

90,000

Offering

Class Of Warrant Or Right [Line Items]

Class of warrant or right issued

750,000

Strike price

$ 3.75

Class of warrant or right, date from which warrants or rights exercisable

Jun. 15, 2022

Selling, General and Administrative

Class Of Warrant Or Right [Line Items]

Warrant expense

$ 87,597

210,848

Selling, general and administrative

$ 685,441

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net loss	$ (18,054,155)	$ (14,786,063)
Denominator:
Net loss per share - basic	$ (0.72)	$ (0.81)
Net loss per share - diluted	$ (0.72)	$ (0.81)
Weighted average number of common share - diluted	25,211,726	18,209,198
Weighted average number of common share - basic	25,211,726	18,209,198

Net Loss Per Share - Summary _2

Net Loss Per Share - Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	5,956,282	5,158,357
Options to Purchase Shares of Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	4,394,369	3,596,444
Warrants to Purchase Shares of Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	1,561,913	1,561,913

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Taxes [Line Items]
Deferred tax asset, increase in valuation allowance	$ 4,900,000	$ 3,800,000
Uncertain tax position impact effective tax rate	0	$ 0
Domestic Tax Authority
Income Taxes [Line Items]
Net operating loss carryforwards	$ 1,600,000
Operating Loss Carryforwards Expiration Year	2030
Operating Loss With No Expiration	$ 24,500,000
Capitalized Research And Development Expenses	$ 9,800,000
Amortisation Of Research And Developmental Cost	5 years
State [Member]
Income Taxes [Line Items]
Provision or benefit for income tax	$ 0
Net operating loss carryforwards	$ 24,400,000
Operating Loss Carryforwards Expiration Year	2030
Foreign Tax Authority
Income Taxes [Line Items]
Capitalized Research And Development Expenses	$ 2,000,000
Amortisation Of Research And Developmental Cost	15 years

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Tax at statutory rate	21%	21%
State income taxes	6.17%	4.89%
Stock-based compensation	0%	(0.13%)
Other	0.03%	0.02%
Change in valuation allowance	(27.20%)	(25.78%)
Effective tax rate	0%	0%

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carryforwards	$ 6,890,275	$ 5,202,047
Deferred Tax Assets Capitalized Research And Development	2,854,530	0
Stock-based compensation	2,440,885	2,272,970
Accrued expenses	199,961	0
Total deferred tax assets	12,385,651	7,475,017
Deferred tax asset valuation allowance	(12,385,651)	(7,475,017)
Net deferred tax asset	$ 0	$ 0

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)			12 Months Ended
	Apr. 18, 2022	Jun. 08, 2010 USD ($) Agreements shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Loss Contingencies [Line Items]
Total potential milestone payments			$ 5,625,000
Right-of-use asset			328,643	$ 0
Operating Lease, Liability, Total			351,288
Operating Lease Liability Current			145,836
Operating Lease Liability Non current			205,451
Prepaid Expenses And Other Current Assets Member
Loss Contingencies [Line Items]
Lease Security Deposit			25,000
Emory University License Agreements
Loss Contingencies [Line Items]
License agreements, fair value of shares issued		$ 313,500
Number of license agreements | Agreements		2
License agreement description		the License A term is the later of 10 years or until the expiration of the patent rights. License B was terminated in May 2013 under the normal course of business
Total potential milestone payments		$ 280,000	0	$ 0
Emory University License Agreements | License A [Member]
Loss Contingencies [Line Items]
License agreements, shares issued | shares		393,370
License agreement, term		10 years
Emory University License Agreements | License B [Member]
Loss Contingencies [Line Items]
License agreements, fair value of shares issued		$ 437,078
Sphaera Agreement
Loss Contingencies [Line Items]
License agreement, fixed fee paid			$ 160,000
Lexington [Member]
Loss Contingencies [Line Items]
Lease Expiration Date	Sep. 30, 2025
Operating Lease Period			2 years 6 months
Incremental Borrowing Rate			12%
Right-of-use asset			$ 328,643
Operating Lease, Liability, Total			$ 351,287
Lessor, Operating Lease, Description			The Office Lease contains escalating payments during the lease period. Upon execution of the Office Lease, the Company prepaid one month of rent and a security deposit, one of which will be held in escrow and credited at the termination of the lease and the other of which will be applied to the first month’s rent.

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)	Dec. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2023	$ 145,836
2024	150,095
2025	114,966
Total lease payment	410,897
Less: imputed interest	(59,609)
Operating Lease, Liability, Total	$ 351,288
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Operating Lease, Liability, Total

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Milestone Payment (Details)	Dec. 31, 2022 USD ($)
Revenue Recognition Milestone Method [Line Items]
Total potential milestone payments	$ 5,625,000
First Dosing of Patient In U S Phase1 Trial
Revenue Recognition Milestone Method [Line Items]
Total potential milestone payments	250,000
US Phase 1 Trial Completion with Endpoints Met
Revenue Recognition Milestone Method [Line Items]
Total potential milestone payments	500,000
US Phase 2 Trial Completion with Endpoints Met
Revenue Recognition Milestone Method [Line Items]
Total potential milestone payments	875,000
FDA Approval
Revenue Recognition Milestone Method [Line Items]
Total potential milestone payments	$ 4,000,000

Simple Retirement Account for_2

Simple Retirement Account for Employees (the "Simple IRA") - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Retirement Benefits [Abstract]
Individual retirement plan, coverage requirement, minimum compensation amount received during two preceding years	$ 5,000
Individual retirement plan, coverage requirement, minimum compensation amount reasonably expected to received	$ 5,000
Individual retirement plan, percentage of qualified compensation match	3%
Compensation contributions under simple IRA	$ 48,408	$ 28,938

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions							1 Months Ended	12 Months Ended
	Mar. 28, 2023	Jan. 25, 2023	Dec. 28, 2020	Aug. 25, 2020	Mar. 31, 2020	Jan. 01, 2019	Oct. 31, 2018	Dec. 31, 2022	Dec. 31, 2021	Oct. 27, 2021	Feb. 05, 2020
Subsequent Event [Line Items]
Exercise price			$ 10	$ 5.9	$ 5.67	$ 4.79				$ 4.79	$ 4.87
Class of warrant or right issued			102,435	150,000	26,225	20,533	400,866
Class Of Warrant Or Right Exercised In Period								0	0
Subsequent Event Member
Subsequent Event [Line Items]
Number of common stock sold		2,800,789
Share price per share		$ 0.86
Exercise price		$ 0.86
Class of warrant or right issued		11,627,908
Class Of Warrant Or Right Exercised In Period	3,028,398
Receive net proceeds from Registered Direct Offering		$ 8.7
Subsequent Event Member | Pre Funded Warrants [Member]
Subsequent Event [Line Items]
Exercise price		$ 0.86
Warrants Expiry date		Jan. 27, 2028
Class of warrant or right issued		8,827,119
Subsequent Event Member | Placement Agent Warrants [Member]
Subsequent Event [Line Items]
Exercise price		$ 1.075
Warrants Expiry date		Jan. 25, 2028
Class of warrant or right issued		406,977